Literature DB >> 24685054

Sphingosine kinase 1 improves cutaneous wound healing in diabetic rats.

Hongyang Yu1, Lizhen Yuan2, Mingbo Xu3, Zhenqing Zhang4, Haifeng Duan5.   

Abstract

BACKGROUND: Diabetes is one of the most prevalent human metabolic diseases. Wound healing in diabetes is frequently impaired and treatment remains challenging. Sphingolipid metabolites play important roles in the regulation of glucose metabolism. SPK1 is the key enzyme in the sphingolipid metabolic pathway. S1P/SPK plays a pivotal role in the signalling pathways of diverse cellular processes including proliferation, differentiation, migration, apoptosis in diverse cell types.
METHODS: To investigate the role of sphingosine kinase 1 (SPK1) in skin injury, plasmids containing the SPK1 gene (pcDNA3-FLAG-SPK1) were applied to cutaneous wounds on a streptozotocin-induced diabetic rat model over a 21-day period. The wound area and rate of wound healing were determined. The histopathological features of the healed wounds were also observed, and SPK1 expression in the skin was detected by immunohistochemistry.
RESULTS: There was a significant decrease in wound area in diabetic rats treated with 125 and 60μg/wound pcDNA3-FLAG-SPK1 (P<0.001-0.01). The mean sizes of the wounds were 0.67±0.15cm(2), 0.83±0.18cm(2), and 1.09±0.23cm(2) in both treated and diabetic control group at the 7th day post-treatment respectively. In addition, wound healing in diabetic rats of test group was accelerated. At the 7th day, the mean rates of healing were 73.2±5.7% and 66±7.3% in test group of 125 and 60μg/wound respectively, and 55.4±9.9% in diabetic control group (P<0.001-0.01). Histology revealed that tissue sections from the treated diabetic rats contained more granulation tissue and capillaries than that of the control rats. There was high SPK1 expression in the skin of the treated diabetic rats.
CONCLUSIONS: SPK1 gene therapy may represent a novel approach to cutaneous wound healing.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Diabetic rats; Diabetic wound healing; Sphingosine kinase 1

Mesh:

Substances:

Year:  2014        PMID: 24685054     DOI: 10.1016/j.injury.2014.03.003

Source DB:  PubMed          Journal:  Injury        ISSN: 0020-1383            Impact factor:   2.586


  6 in total

Review 1.  Metabolomics: Impact of Comorbidities and Inflammation on Sickness Behaviors for Individuals with Chronic Wounds.

Authors:  Junglyun Kim; Gee Su Yang; Debra Lyon; Debra L Kelly; Joyce Stechmiller
Journal:  Adv Wound Care (New Rochelle)       Date:  2020-09-18       Impact factor: 4.947

Review 2.  Switching the sphingolipid rheostat in the treatment of diabetes and cancer comorbidity from a problem to an advantage.

Authors:  Nikolas K Haass; Najah Nassif; Eileen M McGowan
Journal:  Biomed Res Int       Date:  2015-03-19       Impact factor: 3.411

Review 3.  Sphingosine-1-Phosphate Signaling in Immune Cells and Inflammation: Roles and Therapeutic Potential.

Authors:  Masayo Aoki; Hiroaki Aoki; Rajesh Ramanathan; Nitai C Hait; Kazuaki Takabe
Journal:  Mediators Inflamm       Date:  2016-02-07       Impact factor: 4.711

Review 4.  The role of sphingolipid signalling in diabetes‑associated pathologies (Review).

Authors:  Mei Li Ng; Carol Wadham; Olga A Sukocheva
Journal:  Int J Mol Med       Date:  2017-01-11       Impact factor: 4.101

Review 5.  Mammalian sphingosine kinase (SphK) isoenzymes and isoform expression: challenges for SphK as an oncotarget.

Authors:  Diana Hatoum; Nahal Haddadi; Yiguang Lin; Najah T Nassif; Eileen M McGowan
Journal:  Oncotarget       Date:  2017-05-30

6.  bFGF-Regulating MAPKs Are Involved in High Glucose-Mediated ROS Production and Delay of Vascular Endothelial Cell Migration.

Authors:  Zhong Xin Zhu; Wan Hui Cai; Tao Wang; Hong Bo Ye; Yu Ting Zhu; Li Sha Chi; Yuan Meng Duan; Cong Cong Sun; Yuan Hu Xuan; Li Tai Jin
Journal:  PLoS One       Date:  2015-12-07       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.